Company Active LTD

Company profile

F2G Ltd

F2G Privacy Policy

F2G Ltd is a UK company with status active founded in 1998 based in North West England.

CRN
03578625
Founded
1998
Age
28

Overview

Legal name
F2G LTD
Region
North West England
Registered address
LAB B, GROUND FLOOR BLOCK 50 ALDERLEY PARK
NETHER ALDERLEY
MACCLESFIELD
CHESHIRE
UNITED KINGDOM
SK10 4TG
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

10 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

24 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

10 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

20 Feb
2025

Capital Allotment Shares

Capital

SH01 | Transaction MzQ1NTQ3MzU3NWFkaXF6a2N4 | Paper/PDF filed

Published 21 Feb 2025 07:06

19 Feb
2025

Capital Allotment Shares

Capital

SH01 | Transaction MzQ1NTQ3MzU3NGFkaXF6a2N4 | Paper/PDF filed

Published 20 Feb 2025 05:56

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

05 Oct
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQzODI2ODQ5NGFkaXF6a2N4 | Paper/PDF filed

Published 08 Oct 2024 06:34

30 Sep
2024

Accounts With Accounts Type Group

Accounts PDF pending

AA | Transaction MzQzNzE3Nzc4NmFkaXF6a2N4 | Paper/PDF filed

Published 01 Oct 2024 06:27

15 Aug
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQzMjE1MzUyOGFkaXF6a2N4 | Paper/PDF filed

Published 15 Aug 2024 14:45

10 Jun
1998

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2014
Funded years
2014, 2017
Age at first award
16 years

Projects

2017 Collaborative R&D Lead participant

Development of a broad spectrum antifungal series

1 Aug 2017 to 31 Jul 2019

Awarded
£709,876
Total cost £1,014,109

Invasive fungal infections kill 1.5 million people worldwide per year. New antifungal drugs are urgently needed to combat the increasing mortality from these diseases and to supplement the limited therapeutic options. In particular new antifungals with novel mechanisms of action are required to address the worrying rise in resistance to current therapies....

2014 Collaborative R&D Lead participant

Phase I oral safety assessment of a novel antifungal for systemic fungal infections

1 Oct 2014 to 31 Oct 2016

Awarded
£1,331,296
Total cost £2,218,826

Systemic fungal disease is a life threatening groups of infections caused by yeasts and moulds that affects people who have impaired immune systems. The numbers of patients are increasing and the current threatment options are limited to three types of antifungal drug. Often these drugs have severe side effects or can't be used with other medicines. F2G h...

Product types

Collaborative R&D